Remarks/Arguments

Applicants have amended the specification to provide the priority claim. The claims have been amended to remove multiple dependencies, correct typographical errors and to otherwise place the claims in an appropriate U.S. format. No new matter has been added by these amendments.

The above amendments have been made without prejudice to Applicants right to prosecute any cancelled subject matter in a timely filed continuation application.

Although Applicants believe no fees are due, the Commissioner is hereby authorized to charge any deficiency in the fees or credit any overpayment to deposit account No. 50-3231, referencing Attorney Docket No. 101064-1P US.

Respectfully submitted,

Name: Dated: Carol A. Loeschorn 14 February 2006

Reg. No.:

35,590

Phone No.: 781-839-4002

Global Intellectual Property, Patents AstraZeneca R&D Boston 35, Gatehouse Drive Waltham, MA 02451